Current treatment for primary ciliary dyskinesia conditions

Young Yoo, Young Yull Koh

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Primary ciliary dyskinesia (PCD) is a heterogeneous group of conditions characterised by ultrastructural defects of the cilia, which result in impaired mucociliary clearance. Although the incidence of PCD is low, early recognition and prompt management are important in order to prevent unnecessary morbidity, the progression of bronchiectasis and the deterioration of lung function. As the underlying defect in PCD cannot be corrected, the mainstay of therapy remains effective clearance of airway secretions and antibiotic therapy of respiratory tract infections. This paper highlights new developments in the field that have implications for the future management of PCD. These include β-adrenergic agonists, arginine, uridine-5′-triphosphate, hypertonic saline and recombinant human DNase. It is to be hoped that these treatment modalities will have a therapeutic role in PCD.

Original languageEnglish
Pages (from-to)369-377
Number of pages9
JournalExpert Opinion on Pharmacotherapy
Volume5
Issue number2
DOIs
Publication statusPublished - 2004 Feb 1
Externally publishedYes

Fingerprint

Kartagener Syndrome
Mucociliary Clearance
Adrenergic Agonists
Uridine Triphosphate
Bronchiectasis
Cilia
Respiratory Tract Infections
Arginine
Therapeutics
Anti-Bacterial Agents
Morbidity
Lung
Incidence

Keywords

  • β-adrenergic agonists
  • Arginine
  • Current treatment
  • Hypertonic saline
  • Mucociliary clearance
  • Primary ciliary dyskinesia
  • Recombinant human DNase
  • Uridine-5′-triphosphate

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Current treatment for primary ciliary dyskinesia conditions. / Yoo, Young; Koh, Young Yull.

In: Expert Opinion on Pharmacotherapy, Vol. 5, No. 2, 01.02.2004, p. 369-377.

Research output: Contribution to journalReview article

@article{8eb48cd989694c409f6e58cf2f8c9280,
title = "Current treatment for primary ciliary dyskinesia conditions",
abstract = "Primary ciliary dyskinesia (PCD) is a heterogeneous group of conditions characterised by ultrastructural defects of the cilia, which result in impaired mucociliary clearance. Although the incidence of PCD is low, early recognition and prompt management are important in order to prevent unnecessary morbidity, the progression of bronchiectasis and the deterioration of lung function. As the underlying defect in PCD cannot be corrected, the mainstay of therapy remains effective clearance of airway secretions and antibiotic therapy of respiratory tract infections. This paper highlights new developments in the field that have implications for the future management of PCD. These include β-adrenergic agonists, arginine, uridine-5′-triphosphate, hypertonic saline and recombinant human DNase. It is to be hoped that these treatment modalities will have a therapeutic role in PCD.",
keywords = "β-adrenergic agonists, Arginine, Current treatment, Hypertonic saline, Mucociliary clearance, Primary ciliary dyskinesia, Recombinant human DNase, Uridine-5′-triphosphate",
author = "Young Yoo and Koh, {Young Yull}",
year = "2004",
month = "2",
day = "1",
doi = "10.1517/14656566.5.2.369",
language = "English",
volume = "5",
pages = "369--377",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Current treatment for primary ciliary dyskinesia conditions

AU - Yoo, Young

AU - Koh, Young Yull

PY - 2004/2/1

Y1 - 2004/2/1

N2 - Primary ciliary dyskinesia (PCD) is a heterogeneous group of conditions characterised by ultrastructural defects of the cilia, which result in impaired mucociliary clearance. Although the incidence of PCD is low, early recognition and prompt management are important in order to prevent unnecessary morbidity, the progression of bronchiectasis and the deterioration of lung function. As the underlying defect in PCD cannot be corrected, the mainstay of therapy remains effective clearance of airway secretions and antibiotic therapy of respiratory tract infections. This paper highlights new developments in the field that have implications for the future management of PCD. These include β-adrenergic agonists, arginine, uridine-5′-triphosphate, hypertonic saline and recombinant human DNase. It is to be hoped that these treatment modalities will have a therapeutic role in PCD.

AB - Primary ciliary dyskinesia (PCD) is a heterogeneous group of conditions characterised by ultrastructural defects of the cilia, which result in impaired mucociliary clearance. Although the incidence of PCD is low, early recognition and prompt management are important in order to prevent unnecessary morbidity, the progression of bronchiectasis and the deterioration of lung function. As the underlying defect in PCD cannot be corrected, the mainstay of therapy remains effective clearance of airway secretions and antibiotic therapy of respiratory tract infections. This paper highlights new developments in the field that have implications for the future management of PCD. These include β-adrenergic agonists, arginine, uridine-5′-triphosphate, hypertonic saline and recombinant human DNase. It is to be hoped that these treatment modalities will have a therapeutic role in PCD.

KW - β-adrenergic agonists

KW - Arginine

KW - Current treatment

KW - Hypertonic saline

KW - Mucociliary clearance

KW - Primary ciliary dyskinesia

KW - Recombinant human DNase

KW - Uridine-5′-triphosphate

UR - http://www.scopus.com/inward/record.url?scp=1242341944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242341944&partnerID=8YFLogxK

U2 - 10.1517/14656566.5.2.369

DO - 10.1517/14656566.5.2.369

M3 - Review article

VL - 5

SP - 369

EP - 377

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 2

ER -